Latest Breaking News On - Breakthrough therapy designations - Page 5 : comparemela.com

AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting

AACR 2024 | Ascentage Pharma Presents Results from Three Studies at 2024 American Association of Cancer Research Annual Meeting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongSan diegoPrnewswire ascentage pharmaYifan zhaiAscentage pharmaMajor nationalChina national medical products administrationNational reimbursement drug listMd anderson cancer centerAmerican association of cancer research annual meetingDana farber cancer instituteAscentage pharma presents resultsThree studiesCancer research annualCancer research annual meeting

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Acquisition adds taletrectinib, a next-generation,.

United statesNew yorkSan franciscoCayman islandsDaiichi sankyoJunyuan jerry wangInnovent biologicsNuvation bioWalkers caymanMorrison foerster llpExchange commissionMorrison foersterDrug administrationChina national medical products administrationDavis polk wardwellAnheart therapeutics ltd

Nuvation Bio Buys AnHeart Therapeutics

Nuvation Bio Buys AnHeart Therapeutics
themiddlemarket.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themiddlemarket.com Daily Mail and Mail on Sunday newspapers.

Cayman islandsNuvation bioDavis polk wardwellNuvation bio incAnheart therapeutics ltdMorrison foerster llpMorrison foersterChina national medical products administrationDrug administrationBreakthrough therapy designationsChina national medical productsFangda partners

Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA

Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesWestern australiaHong kongPrnewswire ascentage pharmaDajun yangAscentage pharmaMd anderson cancer centerMajor nationalChina national medical products administrationDrug administrationDana farber cancer instituteNational comprehensive cancer networkNational reimbursement drug listGlobal multicenterChronic phase myeloid leukemiaMain board

U S Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb s Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors | Region

PRINCETON, N.J. (BUSINESS WIRE) Feb 14, 2024

Joseph fioreBristol myers squibbBristol myers squibb companyDrug administrationExchange commissionMyers squibbNew drug applicationPriority reviewPrescription drug user fee actBristol myersPoint therapeuticsResponse evaluation criteriaSolid tumorsBlinded independent central reviewPositive solidBetter future